DAFTAR PUSTAKA

Afkarian, M., Zelnick, L.R., Hall, Y.N., Heagerty, P.J., Tuttle, K., Weiss, N.S., et al., (2016). Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. *JAMA*;316:602-610.

Ajay, A.K, Kim, T.M., Ramirez-Gonzalez, V., Park, P.J., Frank, D. A. and Vaidya, V.S. (2014). A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury. *J Am Soc Nephrol*; 25: 105-18.

Alderson, H. V., Ritchie, J.P., Pagano, S., Middleton, R.J., Pruijm, M., Vuilleumier, N. and Kalra, P.A. (2016). The associations of blood kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin with progression from CKD to ESRD. *Clin J Am Soc Nephrol*; 11: 2141-2149.

Alicic, R. Z., Roone, M. T., Tuttle, K. R. (2017). Diabetic Kidney Disease Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol;* 12: 2032–2045.

Alva, M.L., Gray, A., Mihaylova, B., Leal, J., Holman, R.R. (2015). The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). *Diabetic Medicine*;32:459-466.

Amann, B., Tinzmann, R., Angelkort, B. (2003). ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. *Diabetes Care*; 26: 2421-5.

American Diabetes Association. (2020). 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020. *Diabetes Care*, *43*(Supplement 1): S135-S151.

Aregbesola, A., Voutilainen, S., Virtanen, J. K., Mursu, J., & Tuomainen, T. P. (2017). Gender difference in type 2 diabetes and the role of body iron stores. *Annals of clinical biochemistry*, *54*(1), 113–120. https://doi.org/10.1177/0004563216646397

Bailly, V., Zhang, Z., Meier, W., Cate, R., Sanicola, M. and Bonventre, J.V. (2002). Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. *J Biol Chem*; 277: 39739-48.

Bakris, G. L., Weir, M. R., Shanifar, S., Zhang, Z., Douglas, J., van Dijk, D.J., Brenner, B.M.; RENAAL Study Group. (2003). Effects of blood

pressure level on progression of diabetic nephropathy: Results from the RENAAL study. *Arch Intern Med*;163:1555–1565.

Balasubramanian, S., Kota, S.K., Kuchroo, V.K., Humphreys, B.D. and Strom, T.B. (2012). TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77. *Sci Signal*; 5: ra90.

Bilous, R. (2008). Microvascular disease:What does the UKPDS tell us about diabetic nephropathy?. *Diabet Med;* 25[Suppl 2]: 25–29.

Bulanov, N.M., Serova, A.G., Kuznetsova, E.I., Bulanova, M.L., Novikov, P.I., Kozlovskaya, L.V., Moiseev, S.V. (2017). Kidney injury molecules (KIM-1, MCP-1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibodyassociated glomerulonephritis. *Ter Arkh*; 89: 48-55.

Balu, D., Krishnan, V., Krishnamoorthy, V., Singh, R. B., Narayanasamy, S., Ramanathan, G. (2022). Does serum kidney injury molecule-1 predict early diabetic nephropathy: A comparative study with microalbuminuria. Ann Afr Med;21:136-9

Carter, J.L., Parker, C.T., Stevens, P.E., Eaglestone, G., Knight, S., Farmer, C.K. and Lamb, E.J. (2016). Biological variation of plasma and urinary markers of acute kidney injury in patients with CKD. *Clin Chem*; 62: 876-83.

Castillo-Rodriguez, E., Fernandez-Prado, R., Martin-Cleary, C., Pizarro-Sanchez, M.S., SanchezNino, M.D., et al. (2017). Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease. *Nephron*; 136: 263-267.

Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohlrogge, A.W., et al., (2018). IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Research and Clinical Practice*;138:271-281.

Collier, J.B. and Schnellmann, R.G. (2017). Extracellular signal-regulated kinase 1/2 regulates kidney injury molecule-1 expression physiologically and following ischemic and septic renal injury. *J Pharmacol Exp Ther*; 363: 419-427.

Coca, S. G., Nadkarni, G. N., Huang, Y., Moledina, D. G., Rao, V., Zhang, J., Ferket, B., Crowley, S. T., Fried, L. F., & Parikh, C. R. (2017). Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. *Journal of the American Society of Nephrology : JASN*, *28*(9), 2786–2793. https://doi.org/10.1681/ASN.2016101101

Carlsson, A. C., Calamia, M., Risérus, U., Larsson, A., Helmersson-Karlqvist, J., Lind, L., & Arnlöv, J. (2014). Kidney injury molecule (KIM)-1 is associated with insulin resistance: results from two community-based studies of elderly individuals. *Diabetes research and clinical practice*, *103*(3), 516–521. https://doi.org/10.1016/j.diabres.2013.12.008

DCCT/EDIC Research Group; de Boer, I.H., Sun, W., Cleary, P.A., Lachin, J.M., Molitch, M.E., Steffes, M.W., Zinman, B. (2011). Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med*;365: 2366–2376.

DeKruyff, R.H., Bu, X., Ballesteros, A., Santiago, C., Chim, Y.L., Lee, H.H., Karisola, P., et al. (2010). T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. *J Immunol*; 184: 1918-1930.

Echbarthi, M., Zonca, M., Mellwig, R., Schwab, Y., Kapla, G., DeKruyff, R.H. (2015). Distinct trafficking of cell surface and endosomal TIM-1 to the immune synapse. *Traffic*; 16: 1193-1207.

EL-Attar, H.A., Khalil, G.I., Gaber, E.W. (2017). Human Kidney Injury Molecule-1 (Kim-1) Level as an Early Marker for Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients. *Jour Ren Med*; 1:1.

El-Ashmawy, N. E., El-Zamarany, E. A., Khedr, N. F., El-Fattah, A. I., Eltoukhy, S. A. (2015). Ashmawy Kidney injury molecule-1 (Kim-1): an early biomarker for nephropathy in type II diabetic patients. *Int J Diabetes Dev Ctries*. DOI 10.1007/s13410-015-0403-3

Fang, M., Ganta, K., Arzhan, S., Wagner, B. (2020). Biomarkers in acute kidney disease. *Elsevier* ; 155-184.

Fu, H., Liu, S., Bastacky, S. I., Wang, X., Tian, X. J., Zhou, D. (2019). Diabetic kidney diseases revisited: A new perspective for a new era. *Molecular Metabolism;* 30:250-263.

Fuchsberger, C., Flannick, J., Teslovich, T.M., Mahajan, A., Agarwala, V., Gaulton, K.J., et al. (2016). The genetic architecture of type 2 diabetes. *Nature*;536:41e47.

Forbes, J. M., McCarthy, D. A., Kassianos, A. J., Baskerville, T., Fotheringham, A. K., Giuliani, K., Grivei, A., Murphy, A. J., Flynn, M. C., Sullivan, M. A., Chandrashekar, P., Whiddett, R., Radford, K. J., Flemming, N., Beard, S. S., D'Silva, N., Nisbet, J., Morton, A., Teasdale, S., Russell, A., … O'Moore-Sullivan, T. (2021). T-Cell Expression and Release of Kidney Injury Molecule-1 in Response to

Glucose Variations Initiates Kidney Injury in Early Diabetes. *Diabetes*, *70*(8), 1754–1766. https://doi.org/10.2337/db20-1081

Gardiner, L., Akintola, A., Chen, G., Catania, J.M., Vaidya, V., Burghardt, R.C., et al. (2012). Structural equation modeling highlights the potential of Kim-1 as a biomarker for chronic kidney disease. *Am J Nephrol*; 35: 152-163.

Gosmanov, A.R., Wall, B.M. & Gosmanova, E.O. (2014). Diagnosis and Treatment of Diabetic Kidney Disease. *The American Journal of The Medical Sciences*. 347(5): 406-413.

Guo, L., Takino, T., Endo, Y., Domoto, T. and Sato, H. (2012). Shedding of kidney injury molecule-1 by membrane-type 1 matrix metalloproteinase. *J Biochem*; 152: 425-432.

Gray, N., Picone, G., Sloan, F., & Yashkin, A. (2015). Relation between BMI and diabetes mellitus and its complications among US older adults. *Southern medical journal*, *108*(1), 29–36. https://doi.org/10.14423/SMJ.0000000000000214

Gohda, T., Kamei, N., Koshida, T., Kubota, M., Tanaka, K., Yamashita, Y., Adachi, E., Ichikawa, S., Murakoshi, M., Ueda, S., & Suzuki, Y. (2020). Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. *Journal of diabetes investigation*, *11*(2), 435–440. https://doi.org/10.1111/jdi.13139

Holman, N., Young, B., Gadsby, R. (2015). Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. *Diabetic Medicine*;32: 1119-1120.

Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A.W. (2008). 10- year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*;359: 1577–1589.

Hosohata K. (2017). Biomarkers for chronic kidney disease associated with high salt intake. *Int J Mol Sci*; 18: 2080.

Humphreys, B. D., Xu, F., Sabbisetti, V., Grgic, I., Movahedi Naini, S., Wang, N., Chen, G., Xiao, S., Patel, D., Henderson, J. M., Ichimura, T., Mou, S., Soeung, S., McMahon, A. P., Kuchroo, V. K., & Bonventre, J. V. (2013). Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. *The Journal of clinical investigation*, *123*(9), 4023–4035. https://doi.org/10.1172/JCI45361

Humphreys, B.D. (2012). Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. *Seminars in Nephrology;* 32: 463-470.

Huebschmann, A. G., Huxley, R. R., Kohrt, W. M., Zeitler, P., Regensteiner, J. G., & Reusch, J. (2019). Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. *Diabetologia*, *62*(10), 1761–1772. https://doi.org/10.1007/s00125-019-4939-5

Hosohata, K., Ando, H., Takeshita, Y., Misu, H., Takamura, T., Kaneko, S., & Fujimura, A. (2014). Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. *Diabetes & vascular disease research*, *11*(4), 243–250. https://doi.org/10.1177/1479164114531299

Ichimura, T., Asseldonk, E.J., Humphreys, B.D., Gunaratnam, L., Duffield, J..S. and Bonventre, J.V. (2008). Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. *J Clin Invest*; 118: 1657-1668.

Ismail, O.Z., Zhang, X., Wei, J., Haig, A., Denker, B.M., Suri, R.S., Sener, A. and Gunaratnam, L. (2015). Kidney injury molecule-1 protects against Gα12 activation and tissue damage in renal ischemiareperfusion injury. *Am J Pathol*; 185: 1207-15.

Jiang, X., & Sui, W. (2021). Serum KIM-1, NGAL, and NAG Levels and Correlation with the Diagnostic Value in Patients with Fracture Traumatic Shock. *Evidence-based complementary and alternative medicine : eCAM*, *2021*, 3063229. https://doi.org/10.1155/2021/3063229

Karuranga, S., Huang, Y., Moura, A.F., Rathmann, W., Malanda, B.. (2018). Diabetes prevalence, mortality and healthcare expenditure in 2017 and 2045 in Europe: data from the IDF Diabetes Atlas. *Diabetologia*;61:S139-S140.

Kato, K., Sato, N., Yamamoto, T., Iwasaki, Y.K., Tanaka, K., Mizuno, K. (2008). Valuable markers for contrastinduced nephropathy in patients undergoing cardiac catheterization. *Circ J*;72 (9):1499–505.

Khanam, P.A., Hoqueb, S., Beguma, T., Habibc, S.H., Latif., Z.A. (2017). Microvascular Complications And Their Associated Risk Factors In Type 2 Diabetes Mellitus. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 2017, 11: S577-S581.

Koopman, R. J., Mainous, A. G., 3rd, Diaz, V. A., & Geesey, M. E. (2005). Changes in age at diagnosis of type 2 diabetes mellitus in the United

States, 1988 to 2000. *Annals of family medicine*, *3*(1), 60–63. https://doi.org/10.1370/afm.214

Kuo, I. C., Lin, H. Y., Niu, S. W., Hwang, D. Y., Lee, J. J., Tsai, J. C., Hung, C. C., Hwang, S. J., & Chen, H. C. (2016). Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease. *Scientific reports*, *6,* 20028. https://doi.org/10.1038/srep20028

Kim, S. S., Song, S. H., Kim, I. J., Yang, J. Y., Lee, J. G., Kwak, I. S., & Kim, Y. K. (2012). Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. *Diabetes research and clinical practice*, *97*(2), 251–257. https://doi.org/10.1016/j.diabres.2012.02.019

Kapoula, G. V., Kontou, P. I., & Bagos, P. G. (2020). Diagnostic Performance of Biomarkers Urinary KIM-1 and YKL-40 for Early Diabetic Nephropathy, in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. *Diagnostics (Basel, Switzerland)*, *10*(11), 909. https://doi.org/10.3390/diagnostics10110909

Lim, A.I., Chan, L.Y., Lai, K.N., Tang, S.C., Chow, C.W., Lam, M.F. and Leung, J.C. (2012). Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells. *Int J Biochem Cell Biol*; 44: 1040-1050.

Lin, Q., Chen, Y., Lv, J., Zhang, H., Tang, J., Gunaratnam, L., Li, X., & Yang, L. (2014). Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation. *American journal of physiology. Renal physiology*, *306*(8), F885–F895. https://doi.org/10.1152/ajprenal.00331.2013

Marshall S.M & Flyvbjerg A. (2017). Diabetic Nephropathy. In R. G. Holt, C. Cockram, A. Lyvbjerg, B. J.Goldstein, *Textbook of Diabetes* (FIFTH EDITION), Wiley Blackwell: 566-576

McFarlane, P., Cherney, D., Gilbert, R.E. & Senior, P. (2018). Chronic Kidney Disease In Diabetes. *Canadian Journal Of Diabetes.* 42: S201-S209.

Menke, A., Casagrande, S., Geiss, L., Cowie, C.C. (2015). Prevalence of and trends in diabetes among adults in the United States, 1988-2012. *JAMA*;314: 1021–1029.

Najafian, B., Fogo, A.B., Lusco, M.A., Alpers, C.E. (2015). AJKD Atlas of renal pathology: diabetic nephropathy. *American Journal of Kidney Diseases*;66: e3-e38.

Nathan, D. M; DCCT/EDIC Research Group. (2014). The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: *Overview.Diabetes Care*; 37: 9–16.

National Kidney Foundation. (2012). KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis*; 60: 850–886.

Nazar, C.M.J. (2014). Diabetic Nephropathy; Principles of Diagnosis and Treatment of Diabetic Kidney Disease. *Journal of Nephropharmacology*. 3(1): 15.

Nauta, F. L., Boertien, W. E., Bakker, S. J., van Goor, H., van Oeveren, W., de Jong, P. E., Bilo, H., & Gansevoort, R. T. (2011). Glomerular and tubular damage markers are elevated in patients with diabetes. *Diabetes care*, *34*(4), 975–981. https://doi.org/10.2337/dc10-1545

Nowak, N., Skupien, J., Niewczas, M. A., Yamanouchi, M., Major, M., Croall, S., Smiles, A., Warram, J. H., Bonventre, J. V., & Krolewski, A. S. (2016). Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. *Kidney international*, *89*(2), 459–467. https://doi.org/10.1038/ki.2015.314

Nielsen, S. E., Reinhard, H., Zdunek, D., Hess, G., Gutiérrez, O. M., Wolf, M., Parving, H. H., Jacobsen, P. K., & Rossing, P. (2012). Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. *Diabetes research and clinical practice*, *97*(1), 71–76. https://doi.org/10.1016/j.diabres.2012.02.007

Parving, H.H., Mauer, M., Ritz, E. (2008). Diabetic nephropathy. In: Brenner BM, editor. The kidney. 8th ed. Philadelphia: *WB Saunders*; p.1265-98.

PERKENI. (2019). Pedoman Pengelolahan dan Pencegahan Diabetes Melitus TIpe 2 Dewasa di Indonesia 2019. Jakarta: 1-100

Persson, F. & Rossing, P. (2018). Diagnosis of Diabetic Kidney Disease: State of The Art and Future Perspective. *Kidney International Supplements*. 8(1): 2-7.

Pohl, M.A., Blumenthal, S., Cordonnier, D.J., De Alvaro, F., Deferrari, G., Eisner, G., et al. (2005). Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal

outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. *J Am Soc Nephrol*;16: 3027–3037.

Pugliese, G. (2014). Updating the natural history of diabetic nephropathy. *Acta Diabetol*; DOI 10.1007/s00592-014-0650-7.

Powers, A. C. (2017). Diabetes Mellitus: Complications. In D. L. Kasper, S. L. Hauser, J. L. Jameson, A. S. Fauci & L. Longo, J. Loscalzo, Harrison's Endocrinology (4th Edition). McGraw-Hill: 317-329.

Qi, C., Mao, X., Zhang, Z. & Wu, H. (2017). Classification and Differential Diagnosis of Diabetic Nephropathy. *Journal of Diabetes Research*. 2017.

Quang, T. H., Nguyet, M. P., Thao, D. P., et al. (2020). Evaluation of Urinary Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1 as Diagnostic Markers for Early Nephropathy in Patients with Type 2 Diabetes Mellitus. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*:13 2199–2207.

Reidy, K., Kang, H.M., Hostetter, T. & Susztak, K. (2014). Molecular Mechanisms of Diabetic Kidney Disease. *The Journal of Clinical Investigation*. 124(6): 2333-2340.

Remuzzi, G., Schieppati, A., Ruggenenti, P. (2002). Nephropathy in patients with type 2 Diabetes. *N Engl J Med*; 346: 1145- 51.

Rodriguez-Manzanet, R., Sanjuan, M.A., Wu, H.Y., Quintana, F.J., Xiao, S., Anderson, A.C., Weiner, H.L., Green, D.R., Kuchroo, V.K. (2010). T and B cell hyperactivity and autoimmunity associated with nichespecific defects in apoptotic body clearance in TIM-4-deficient mice. *Proc Natl Acad Sci*; 107: 8706-8711.

Sabbisetti, V.S., Waikar, S.S., Antoine, D.J., Smiles, A., Wang, C., Ravisankar, A. (2014). Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. *J Am Soc Nephrol*; 25: 2177-2186.

Santiago, C., Ballesteros, A., Tami, C., Martinez Munoz, L., Kaplan, G.G. and Casasnovas, J.M. (2007). Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. *Immunity*; 26: 299-310.

Saran, R., Robinson, B., Abbott, K.C., Agodoa, L.Y.C., Bhave, N., BraggGresham, J., et al., (2018). US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. *American Journal of Kidney Diseases*;71:A7.

Schweigert, O., Dewitz, C., Moller-Hackbarth, K., Trad, A., Garbers, C., Rose-John, S. and Scheller, J. (2014). Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. *Biochim Biophys Acta*; 1843: 275-287.

Shahbaz, S.K., Pourrezagholi, F., Barabadi, M., Foroughi, F., Hosseinzadeh, M., Ahmadpoor, P., Nafar, M., Yekaninejad, M. S. and Amirzargar, A. 2017). High expression of TIM-3 and KIM-1 in blood and urine of renal allograft rejection patients. *Transpl Immunol*; 43-44: 11-20.

Shahbazian, H., Rezaii, I. (2013). Diabetic kidney disease; review of the current knowledge. *J Renal Inj Prev*; 2(2): 73-80.

Shahbazian, H., Shahbazian, H., Ahmad Zadeh, A., Latifi, S.M. (2006). Prevalence and risk factors of microalbuminuria in type 2 diabetes mellitus. *Scientific Medical Journal of Ahvaz Jondishapur University of Medical Sciences*; 4: 317-22.

Song, J., Yu, J., Prayoga, G. W., Cao, W., Wu, Y., Jia, Z., Zhang, A. (2019). Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology. *Am J Transl Res*;11(3):1219-1229.

Standards of medical care in diabetes-2016. (2016). Summary of revisions. Diabetes Care 39[Suppl 1]: S4–S5.

Tian, L., Shao, X., Xie, Y., Wang, Q., Che, X., Zhang, M., Xu, W., Xu, Y., Mou, S., & Ni, Z. (2017). Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, *41*(2), 769–783. https://doi.org/10.1159/000458737

Tuttle, K.R., Bakris, G.L., Bilous, R.W., Chiang, J.L., de Boer, I.H., Goldstein Fuchs, J., et al. (2014). Diabetic kidney disease: A report from an ADA consensus conference. *Diabetes Care;* 37: 2864–2883.

Tziomalos, K. & Athyros, V.G. (2015). Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. *The Review of Diabetic Studies: RDS*. 12(1-2): 110.

Tuttle, K. R., & Alicic, R. Z. (2021). Glycemic Variability and KIM-1-Induced Inflammation in the Diabetic Kidney. *Diabetes*, *70*(8), 1617–1619. https://doi.org/10.2337/dbi21-0021

van Zuydam, N.R., Ahlqvist, E., Sandholm, N., Deshmukh, H., Rayner, N.W., Abdalla, M., et al. (2018). A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes. *Diabetes*;67:1414-1427.

Waikar, S.S., Sabbisetti, V., Arnlov, J., Carlsson, A.C., Coresh, J., Feldman, H.I., et al. (2016). Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. *Nephrol Dial Transplant*; 31: 1460-1470.

White, K.E., Marshall, S.M., Bilous, R.W. (2008). Prevalence of atubular glomeruli in type 2 diabetic patients with nephropathy. *Nephrology Dialysis Transplantation;* 23:3539-3545.

Wong, K., Valdez, P.A., Tan, C., Yeh, S., Hongo, J.A., Ouyang, W. (2010). Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. *Proc Natl Acad Sci*; 107: 8712-8717.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA*; 290: 2159-67.

Yang, L., Brooks, C.R., Xiao, S., Sabbisetti, V., Yeung, M.Y., Hsiao, L.L., Ichimura, T., Kuchroo, V. and Bonventre, J.V. (2015). KIM-1-mediated phagocytosis reduces acute injury to the kidney. *J Clin Invest*; 125: 1620-1636.

Yang, W.Y., Dall, T.M., Beronjia, K., Lin, J., Semilla, A.P., Chakrabarti, R., et al. (2018). Economic costs of diabetes in the US in 2017. *Diabetes Care;* 41: 917-928.

Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., Zhu, D., Ge, J., Lin, L., Chen, L., Guo, X., Zhao, Z., Li, Q., Zhou, Z., Shan, G., He, J., … China National Diabetes and Metabolic Disorders Study Group (2010). Prevalence of diabetes among men and women in China. *The New England journal of medicine*, *362*(12), 1090–1101. https://doi.org/10.1056/NEJMoa0908292

Zhang, Z. and Cai, C.X. (2016). Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair via ERK MAPK signaling pathway. *Mol Cell Biochem*; 416: 109-16.

Zhang, Z., Humphreys, B.D. and Bonventre, J.V. (2007). Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by

MAP kinases and juxtamembrane region. *J Am Soc Nephrol*; 18: 2704-14.

Zhao,X., Zhang, Y., Li, L., Mann, D., Imig, J.D., Emmett, N., Gibbons, G. and Jin, L.M. (2011). Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. *Am J Nephrol*; 34: 268-80.

Zheng, Y., Ley, S.H., Hu, F.B., (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*;14:88-98.

Zoungas, S., Arima, H., Gerstein, H.C., Holman, R.R., Woodward, M., Reaven, P., et al. (2017). Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol*;5:431-437.

Lampiran 1. Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 214/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 10 Mei 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22020074	No Sponsor Protokol	
Peneliti Utama	**dr. Lestari**	Sponsor	
Judul Peneliti	Analisis Kadar Kidney Injury Molecule 1 (KIM-1) Serum dan Kidney Injury Molecule 1 (KIM-1) Urine Sebagai Penanda Awal Nefropati Diabetik Pada Pasien Diabetes Mellitus Tipe 2		
No Versi Protokol	**2**	Tanggal Versi	**10 Mei 2022**
No Versi PSP	**2**	Tanggal Versi	**10 Mei 2022**
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **10 Mei 2022** sampai **10 Mei 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

• Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
• Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
• Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
• Menyerahkan laporan akhir setelah Penelitian berakhir
• Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
• Mematuhi semua peraturan yang ditentukan

LAMPIRAN 2. Naskah Penjelasan untuk Mendapat Persetujuan dari Subyek Penelitian

NASKAH PENJELASAN UNTUK MENDAPAT PERSETUJUAN DARI SUBYEK PENELITIAN

Selamat pagi Bapak / Ibu / saudara (i), kami dokter yang akan melakukan penelitian mengenai kadar komponen dari darah dan urin yaitu *Kidney Injury Molecule 1* (KIM-1) pada penderita DM. Diabetes melitus adalah penyakit dengan karakteristik tingginya kadar gula dalam darah karena gangguan dari insulin. Salah satu komplikasi DM adalah nefropati diabetik atau penyakit ginjal diabetik. *Kidney Injury Molecule 1* (KIM-1) adalah protein membran tipe I yang terdiri dari bagian ekstraseluler dan bagian sitoplasma. KIM-1 pada ginjal berperan sebagai biomarker awal cedera ginjal akut dan dapat digunakan untuk memprediksi luaran ginjal jangka panjang. Pada cedera tubulus ginjal akut, ekspresi KIM-1 di ginjal meningkat secara signifikan dibandingkan dengan populasi sehat. Begitu juga pada penyakit ginjal kronis (PGK), KIM-1 juga merupakan biomarker sensitif untuk cedera tubulus proksimal kronis . Khusus pada nefropati diabetik, KIM- 1 pada pada serum maupun urin cenderung meningkat seiring dengan peningkatan albuminuria. Besar harapan kami agar penelitian ini dapat memberikan sumbangan ilmu pengetahuan dalam pencegahan komplikasi pada penyakit yang diderita Bapak / Ibu / saudara (i) yaitu penyakit nefropati diabetik.

Adapun penelitian ini tidak memaksa keikutsertaan Bapak / Ibu / saudara (i) dan jika Bapak / Ibu / saudara (i) bersedia menandatangani formulir kesediaan ikut serta dalam penelitian dengan sukarela. Bapak / Ibu / saudara (i) tidak perlu khawatir ketidaksertaan anda dalam penelitian ini tidak mengurangi pelayanan kesehatan yang akan diperoleh dari pihak rumah sakit.

Bila Bapak/Ibu bersedia untuk menjadi responden dalam penelitian ini, maka prosedur yang kami lakukan adalah mengumpulkan sampel darah (minimal 3 cc) dan urin sewaktu (minimal 10 cc) untuk keperluan pemeriksaan laboratorium. dalam penelitian ini, kami akan melakukan pengambilan darah dengan 1 tabung warna merah. Pengambilan darah kami lakukan dengan pungsi vena pada lengan bawah. Volume darah yang diambil minimal 3 cc risiko yang bisa timbul saat pengambilan darah berupa kebiruan diarea suntikan. Hal ini bisa terjadi dan akan perlahan-lahan menghilang. Cara penanganan jika terjadi kebiruan adalah mengompres dengan air dingin, membalut. Bila terjadi perdarahan di area bekas suntikan, dapat dilakukan penekanan guna menghentikan perdarahan dan mengangkat bagian tubuh lebih tinggi dari jantung untuk mengurangi aliran darah ke area yang mengalami perdarahan. Apabila terjadi efek samping yang tidak diinginkan tersebut, baik efek samping pada saat pengambilan darah, akan diberi tata laksana sesuai gejala yang muncul dan hal tersebut merupakan tanggung jawab penuh dari peneliti. Penelitian ini tidak dipungut bayaran sama sekali.

Dalam penelitian ini kami tidak memberikan kompensasi akan tetapi kami akan memberitahu hasil pengukuran kadar *Kidney Injury Molecule 1* (KIM-1) urine dan serum Bapak/Ibu / Saudara (i). Segala biaya dalam pemeriksaan ini sepenuhnya akan ditanggung oleh pihak peneliti sehingga Bapak / Ibu / saudara (i) tidak perlu khawatir.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman, sehingga hanya bisa dilihat oleh yang berkepentingan saja. Data pribadi disamarkan pada semua catatan dan pada pelaporan baik lisan ataupun tertulis tidak akan menggunakan data pribadi.

Bila bapak/ibu merasa masih ada hal yang belum jelas atau belum dimengerti dengan baik, maka ibu dapat menanyakan atau minta penjelasan pada kami dr.Lestari (081349067007)

Penanggung jawab Penelitian
Nama   :   dr. Lestari
Alamat   :   Pondok Raihan BTP Blok M No.191, Kel. Tamalanrea,
**   Kec.Tamalanrea Makassar**
Telepon   :   081349067007

Lampiran 3. Formulir *Informed Consent*

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN

Judul penelitian:
Analisis Kadar *Kidney Injury Molecule 1* (KIM-1) Serum dan *Kidney Injury Molecule 1* (KIM-1) Urine Sebagai Penanda Awal Nefropati Diabetik Pada Pasien Diabetes Mellitus Tipe 2

Saya yang bertanda tangan dibawah ini
Nama   :
Jenis kelamin   :
Umur   :
Alamat   :

      Setelah mendengar dan mengerti penjelasan yang diberikan mengenai tujuan penelitian, dengan ini saya menyatakan bersedia secara sukarela tanpa paksaan dari pihak manapun untuk berpartisipasi dalam penelitian ini dan saya yakin hasilnya bersifat rahasia hanya peneliti utama dan tim komite etik yang mengetahuinya.

      Saya mengetahui bahwa saya berhak untuk menolak atau berhenti dari penelitian ini. Biaya pemeriksaan kadar KIM-1 serum dan KIM-1 urin dalam penelitian ini ditanggung oleh peneliti. Bila masih ada hal yang belum saya mengerti atau saya ingin mendapatkan penjelasan lebih lanjut, saya bisa mendapatkannya dari dokter peneliti sebagai *contact person* (alamat dan nomor telepon tertera di bawah).

                                                            Makassar,

....
……..

Nama subyek   Dokter penanggung jawab
klinis

No. Nama Saksi   Tanda tangan

1. ……………………..   ………………………………………………..

2. ……………………   …………………………………...
………..

Peneliti Utama :   Penanggung Jawab Penelitian :
Nama : dr.Lestari   Nama:Dr.dr.Yuyun Widaningsih,M.Kes,Sp.PK (K)
Telepon : 081349067007   Telepon :081342022247
Alamat: BTP Blok M No.191 Alamat : BTP Blok M no 96

Lampiran 4. Data Penelitian

No	Jenis Kelamin	Usia	Lama DM	Riwayat HT	HbA1c	Kreatinin	eGFR	IMT	Kim-1 Urine	Kim-1 Serum	Kadar Albuminuria
1	L	34	-	-	-	0.8	116	25	0.273	0.296	2
2	P	34	-	-	-	0.6	119	24.9	0.339	0.295	2
3	L	33	-	-	-	0.7	124	25	0.129	0.295	2
4	L	34	-	-	-	0.8	116	21.6	0.993	0.295	5
5	L	38	-	-	-	0.6	127	22.5	0.404	0.295	2
6	P	35	-	-	-	0.7	112	18.6	0.375	1.502	4
7	P	36	-	-	-	0.5	124	21.5	0.609	0.295	8
8	L	35	-	-	-	0.8	115	23.7	0.060	7.540	6
9	P	38	-	-	-	0.9	82	21.5	0.521	7.220	5
10	P	38	-	-	-	0.6	116	22.9	0.292	0.295	14
11	P	34	-	-	-	0.7	113	19.6	0.520	0.295	5
12	P	31	-	-	-	0.5	115	26.3	0.064	0.295	4
13	L	43	-	-	-	1.0	92	25.3	0.196	0.298	5
14	P	35	-	-	-	0.9	83	25.7	0.105	0.298	5
15	L	39	-	-	-	0.9	107	24.8	0.118	0.295	3
16	P	40	-	-	-	0.8	93	25.8	0.554	0.295	2
17	P	35	-	-	-	0.8	96	28.9	0.443	0.324	4
18	L	38	-	-	-	0.8	113	29.7	1.002	0.303	10
19	L	54	2-5	Tidak	7.2	0.9	97	21	0.785	0.296	22
20	L	52	<2	Tidak	5.9	0.8	102	28.1	0.330	0.296	2
21	L	40	5-10	Tidak	8.5	1.2	75	29.7	0.445	0.295	2
22	P	62	<2	Tidak	6.2	0.7	93	33.8	0.430	0.299	3
23	P	46	<2	Tidak	9	0.7	104	27.4	0.234	0.298	5
24	P	64	>10	Tidak	10.6	0.7	92	21.8	0.235	0.353	22
25	P	67	5-10	Tidak	6.6	0.8	76	26	0.767	0.298	8
26	P	72	<2	Tidak	6.0	0.6	91	17	0.718	0.297	9
27	L	60	2-5	Tidak	6.7	1.2	65	27.4	1.098	0.406	7
28	L	63	<2	Ya	6.2	0.9	91	22.4	0.514	0.296	7
29	P	55	2-5	Tidak	8.1	0.7	98	21.2	0.851	0.295	7
30	P	49	<2	Tidak	7.9	0.8	87	29.6	1.642	0.296	14
31	P	67	>10	Tidak	8.9	0.8	77	19.2	0.297	4.401	7
32	P	40	<2	Tidak	7.0	0.5	121	29.7	1.317	0.297	2
33	L	65	5-10	Ya	7.7	1.3	57	29.3	1.224	0.296	15
34	P	70	<2	Ya	5.8	0.7	88	23.8	0.628	0.298	4
35	L	44	<2	Tidak	6.6	0.6	122	17.1	0.663	0.297	6
36	L	64	>10	Tidak	6.6	1.0	79	21.6	0.699	0.297	6

37	L	54	>10	Tidak	9.0	1.3	62	29.8	0.047	0.295	21
38	P	64	>10	Tidak	10	0.4	110	25.1	0.849	0.298	7
39	P	58	<2	Tidak	10.1	0.6	100	20.3	1.217	0.296	6
40	L	61	5-10	Tidak	9.9	1.0	81	21.5	0.216	0.296	2
41	L	37	<2	Tidak	10.4	0.6	116	21.7	0.661	0.317	4
42	P	53	>10	Ya	11.1	0.7	99	25.6	1.687	0.295	12
43	L	57	2-5	Tidak	10.4	0.8	99	20.1	0.606	0.339	13
44	P	71	<2	Tidak	11.6	0.7	87	26.7	1.384	0.312	14
45	L	69	2-5	Tidak	8.2	0.6	102	24.2	0.537	0.297	12
46	P	56	<2	Tidak	8.1	0.5	108	21.8	0.035	0.297	19
47	P	55	5-10	Ya	10	0.9	72	17.5	0.145	0.306	4
48	P	65	>10	Tidak	9.0	0.4	109	21.2	0.434	0.296	6
49	P	56	2-5	Tidak	9.8	0.8	83	25.4	0.751	0.310	3
50	P	65	2-5	Ya	13.2	0.8	77	20.9	0.608	0.296	13
51	P	28	<2	Tidak	11.4	0.7	118	32.5	0.492	0.296	3
52	P	58	>10	Tidak	13.9	0.6	100	19.2	1.029	0.298	26
53	L	57	>10	Tidak	7.1	0.9	94	25	0.933	0.296	27
54	P	58	<2	Ya	7.2	0.5	107	36.7	0.483	0.300	11
55	P	64	>10	Tidak	9.4	0.8	78	29.4	1.096	0.303	65
56	L	84	>10	Tidak	9.2	1.2	55	24.2	0.659	0.299	901
57	P	63	>10	Tidak	11.5	1.1	54	24.2	1.073	0.300	102
58	L	47	<2	Tidak	9.7	0.9	101	28.6	1.150	0.295	260
59	L	61	>10	Tidak	11.0	0.8	96	24.4	1.034	1.184	63
60	L	42	>10	Ya	6.4	1.4	61	20.2	0.467	0.298	747
61	L	76	>10	Tidak	6.7	1.0	72	30.9	1.581	0.298	51
62	L	60	>10	Tidak	7.6	1.0	81	22.9	0.635	0.297	564
63	L	56	>10	Ya	13.6	1.2	67	20.8	0.827	1.277	40
64	L	65	5-10	Ya	7.3	1.1	70	25.5	0.804	0.299	495
65	P	59	>10	Tidak	7.4	0.6	100	27.4	0.691	0.296	130
66	P	44	>10	Ya	11.5	1.1	61	25.4	0.638	0.348	1285
67	L	51	5-10	Tidak	8.5	1.5	53	23	0.570	0.447	2010
68	P	61	<2	Tidak	7.4	1.1	54	23.1	0.983	0.297	155
69	L	69	>10	Tidak	7.7	1.0	76	28.7	0.357	0.299	156
70	P	63	>10	Tidak	10.8	0.7	92	29.6	0.710	0.533	206
71	P	49	>10	Ya	7.9	0.6	107	24.3	0.979	0.296	47
72	P	47	2-5	Tidak	7.9	0.6	108	17.8	1.825	0.301	128
73	L	60	<2	Tidak	8.3	1.0	81	30.4	0.759	1.903	64
74	P	62	5-10	Ya	15.9	2.0	26	30.1	0.441	0.308	135
75	P	50	5-10	Tidak	11.1	1.0	66	21.1	0.639	0.316	456
76	L	68	2-5	Ya	5.7	1.2	62	22.1	0.755	0.303	109
77	P	61	5-10	Ya	6.5	2.0	26	27.1	0.032	0.340	59

78	L	53	>10	Tidak	8.3	0.9	97	19.7	0.567	0.326	145
79	L	60	5-10	Tidak	7.6	1.0	81	24.8	0.366	0.310	721
80	P	48	<2	Tidak	7.6	0.5	114	29.6	0.585	0.347	146
81	P	55	>10	Ya	10.3	0.5	109	23.8	0.667	0.311	75
82	P	50	>10	Ya	6.5	1.2	53	18.7	0.235	0.339	643
83	L	53	>10	Ya	10.8	1.1	76	25.4	0.540	0.298	41
84	P	62	>10	Ya	12.3	0.8	80	24.1	0.734	0.347	376
85	L	62	>10	Ya	6.5	1.8	40	22.5	0.824	0.296	230
86	P	56	2-5	Tidak	5.7	1.5	37	26.8	2.060	0.463	42
87	L	60	5-10	Tidak	8.8	1.1	73	28.3	0.757	0.297	238
88	P	72	>10	Ya	7.2	0.6	91	21.8	0.564	0.299	184

Lampiran 5. Curriculum Vitae

CURRICULUM VITAE

A. DATA PRIBADI

Nama   : dr. Lestari

Tempat, tanggal lahir   : Palangka Raya, 14 mei 1981

Pekerjaan   : Mahasiswa PPDS/ Aparatur Sipil Negar(ASN)

NIP   : C085 181 003 / 19810514 200904 2 003

Pangkat/Golongan   : III D

Alamat   : Pondok Raihan Komplek BTP Blok M No.191

                                       Tamalanrea,Makassar

B. RIWAYAT PENDIDIKAN

NO.	STRATA	INSTITUSI	TEMPAT	TAHUN TAMAT
1	SD	SDN Langkai 20	Palangka Raya	1993
2	SMP	SMP Negeri 2	Palangka Raya	1996
3	SMA	SMA Negeri 2	Palangka Raya	1999
4.	Dokter	Fakultas Kedokteran Univ. Hang Tuah	Surabaya	2007
5	Spesialis (sementara)	Bagian Patologi Klinik FK-UNHAS	Makassar	2018-Sekarang

C. <u>RIWAYAT PEKERJAAN</u>

No	Kedudukan	Instansi	Tempat	Periode
1	Dokter PTT Kemenkes	Puskesmas Pangkoh, Pandih batu	Kabupaten Pulang Pisau	2008-2009
2	Dokter Pertama	Puskesmas Jekan Raya	Palangka Raya	2009-2012
3	Ketua TIM Klinik IMS	Klinik Infeksi Menular Seksual (IMS) Dinas Kesehatan Kota Palangka Raya	Lokalisasi KM 12 Palangka Raya	2009-2012
4	Dokter Muda	Puskesmas Pahandut Kota	Palangka Raya	2012-2017
5	Dokter Muda	Balai Laboratorium Kesehatan Dinas Kesehatan Provinsi Kalimantan Tengah	Provinsi Kalimantan Tengah	2017-sekarang